Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Other

Alan D Adams

A Brian Jones

Richard L Tolman

Derek J Von Langen

Harold B Wood

Conrad Santini

Joel Peter Berger

Jason W Szewczyk

James V Heck

James Francis Dropinski

Hiroo Koyama

Yong Huang

Kun Liu

Soumya P Sahoo

Gregory D Berger

David E Moller

Stanley Leon Freeman

Mark D Leibowitz

Clare E Gutteridge

Alexander Elbrecht

Gaochao Zhou

Karen Lamb MacNaul

Guo-Qiang Shi

Arthur A Patchett

Frank P DiNinno

William H Parsons

Thomas F Walsh

Peter J Sinclair

Donald W Graham

Sheo B Singh

Gary H Rasmusson

Yuan Cheng

Yong Zhang

John J Acton, Iii

Richard B Toupence

Kenneth J Fitch

Bruno Tse

Jeffrey P Bergman

John G Ondeyka

Meng Yang

Nathan G Steinberg

Victoria K Lombardo

Jeffrey Donald Hermes

Wei Han

Shaei Y Huang

Ralph Troy Mosley

Anthony B Jones

Jonthan R Young

Ahren I Green

Aileen Bouffard

Weiguo Lui

Ali Shiafee

A retrofit propulsion apparatus attaches to an avian decoy to provide both propulsion and steering to the decoy under remote control by the user. The retrofit propulsion apparatus attaches to decoys with different keel geometries without the need to modify the retrofit propulsion apparatus for each decoy keel geometry. The apparatus includes a housing that contains electrical circuitry with control circuitry that couples to inboard water propulsion devices to provide thrust and steering to the decoy. A housing cover sealably attaches to the housing to seal the housing. The housing cover includes a slot that receives a vertical member of a decoy keel. The housing includes an angled channel that receives both a decoy with a decoy bottom member with vertical spaced apart sides and a decoy with a decoy bottom member with angled sides.

Retrofit propulsion apparatus for an avian decoy

Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. 

Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment

Bipiperidinyl compounds of the formula: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment

Bipiperidyl compounds of the formula: (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. 

Acyl bipiperidinyl compounds useful as GPR 119 agonists

Substituted cyclopropyl compounds of formula (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. 

A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol. 

Therapeutic compounds for treating dyslipidemic conditions

Compounds of Formula Iand the pharmaceutically acceptable salts and esters thereof, wherein Z is selected from the group consisting of:

The instant invention is concerned with aryl and heteroaryl acetic acid and oxyacetic acid compounds, which are useful as antidiabetic compounds. Compositions and methods for their use in the treatment of diabetes and related diseases and for lowering triglyceride levels are disclosed.

Antidiabetic agents based on aryl and heteroarylacetic acids

The instant invention is concerned with aryl and heteroaryl oxyacetic acid type compounds which are useful antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and related diseases and for lowering triglyceride levels are also disclosed.

Antidiabetic agents

The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.

Benzisoxazole-derived antidiabetic compounds

Compounds of the formula ##STR1## are inhibitors of peptide binding to major histocompatibility complex type II proteins and may be used in the treatment and prevention of autoimmune diseases including: rheumatoid arthritis, Type I diabetes, multiple sclerosis, lupus erythematosis, Graves disease and pemphigus. The present invention also provides novel compositions, methods of treatment employing compounds of the present invention and methods of manufacture of the compounds of structural formula (I).

Inhibitors of peptide binding to MHC class II proteins

Growing community of inventors

Cranford, NJ, United States of America

Alan D Adams